Cumulative sales of 20 billion won in 1 year and 6 months after release. High growth prospects when promoted to first-line treatment. Yuhan Corporation's anti-cancer drug Leclaza is successfully settling in the domestic market. In the second year of its release, it posted sales of 16.1 billion won, breaking the record for annual sales of a new anti-cancer drug developed in Korea. According to IQVIA, a drug research agency on the 24th, Leclaza recorded sales of 16.1 billion won last year. It increased by 4 times from 4.1 billion last year. Leclaza is a non-small cell lung cancer treatment approved as the 31st new drug developed in Korea in January 2021. Patients with locally advanced or metastatic non-small cell lung canc